Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
238 studies found for:    "Vasculitis"
Show Display Options
Rank Status Study
1 Recruiting Pediatric Vasculitis Initiative
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis);   Microscopic Polyangiitis;   Churg Strauss Syndrome (Eosinophilic Granulomatosis With Polyangiitis);   Polyarteritis Nodosa;   Takayasu Arteritis;   Primary CNS Vasculitis;   Unclassified Vasculitis
Intervention:
2 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
3 Completed Reproductive Health in Men and Women With Vasculitis
Conditions: Giant Cell Arteritis;   Takayasu's Arteritis;   Polyarteritis Nodosa;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Behcet's Disease;   Kawasaki Disease;   Henoch-schoenlein Purpura;   Vasculitis, Central Nervous System;   Drug-induced Necrotizing Vasculitis
Intervention:
4 Unknown  Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Condition: Vasculitis
Intervention: Drug: azathioprine
5 Completed MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
Conditions: Vasculitis;   Anti-Neutrophil Cytoplasmic Antibody
Intervention: Drug: mycophenolate mofetil
6 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
7 Completed Steroids and Methotrexate to Treat Systemic Vasculitis
Conditions: Inflammation;   Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: prednisone and methotrexate
8 Completed Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa
Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides;   Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;   Drug: Mycophenolate mofetil,methotrexate
9 Completed Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention:
10 Completed Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Mycophenolate Mofetil
11 Not yet recruiting Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
Condition: ANCA-associated Vasculitis
Interventions: Drug: CCX168 low dose plus standard of care;   Drug: CCX168 high dose plus standard of care;   Other: Placebo BID plus standard of care
12 Completed Correlation of Genetic Polymorphism and Livedo Vasculitis
Conditions: Livedo Vasculitis;   Livedoid Vasculitis;   Livedoid Vasculopathy;   Genetic Pleomorphism;   Leiden Mutation
Intervention:
13 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone
14 Withdrawn Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Retinoic acid;   Drug: Standard of care
15 Completed Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
Conditions: Systemic Lupus Erythematosus;   ANCA Associated Vasculitis
Intervention: Drug: Rituximab
16 Recruiting CMV Modulation of the Immune System in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis;   CMV Infection
Intervention: Drug: Valaciclovir
17 Withdrawn Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Standard of care treatment;   Drug: eculizumab
18 Completed Vasculitis Illness Perception (VIP) Study
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu's Arteritis;   Henoch-Schoenlein Purpura;   Behcet's Disease;   CNS Vasculitis
Intervention:
19 Recruiting A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Condition: Vasculitis
Interventions: Drug: Placebo;   Drug: CCX168
20 Completed Educational Needs of Patients With Systemic Vasculitis
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Vasculitis, Central Nervous System;   Giant Cell Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years